NCT03735225View on ClinicalTrials.gov

Evaluation of the Safety, Tolerability and Bioavailability of Dasiglucagon Following Subcutaneous (SC) Compared to IV Administration

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 7, 2018

Primary Completion Date

June 24, 2019

Study Completion Date

June 24, 2019

Conditions
Hypoglycemia
Interventions
DRUG

Dasiglucagon

Dasiglucagon injection

DRUG

Placebo

Placebo for Dasiglucagon injection

Trial Locations (1)

68167

CRS Clinical Research Services Mannheim GmbH, Mannheim

Sponsors

Lead Sponsor

Zealand Pharma
All Listed Sponsors
lead

Zealand Pharma

INDUSTRY